The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
Rosalie A ScholtesDaniel H van RaalteRicardo Correa-RotterRobert D TotoHiddo J Lambers HeerspinkValerie CainC David SjöströmPeter SartipyBergur V StefánssonPublished in: Diabetes, obesity & metabolism (2019)
Treatment with dapagliflozin over 24 weeks provides similar clinically relevant improvements in metabolic and haemodynamic parameters, and similar reductions in UACR, in patients with T2D with elevated albuminuria treated with or without RASi at baseline.
Keyphrases